HEALTH CATALYST, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.03 USD | +7.68% |
|
+8.06% | -34.88% |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 10 | KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,269 | 1,850 | 2,062 | 582 | 532.9 | 353.1 | - | - |
| Enterprise Value (EV) 1 | 1,089 | 1,748 | 1,798 | 445 | 443.2 | 683 | 663.6 | 353.1 |
| P/E ratio | -20.9 x | -15 x | -12.3 x | -4.04 x | -4.43 x | -6.08 x | -7.34 x | -20.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.19 x | 9.8 x | 8.53 x | 2.11 x | 1.8 x | 1.14 x | 1.02 x | 0.9 x |
| EV / Revenue | 7.03 x | 9.26 x | 7.43 x | 1.61 x | 1.5 x | 2.21 x | 1.93 x | 0.9 x |
| EV / EBITDA | -39.8 x | -82.1 x | -160 x | -179 x | 40.2 x | 27.7 x | 17.8 x | 6.6 x |
| EV / FCF | -31.5 x | -49.4 x | -53.6 x | -11.9 x | -12.9 x | -137 x | -86.6 x | -373 x |
| FCF Yield | -3.18% | -2.02% | -1.87% | -8.41% | -7.74% | -0.73% | -1.15% | -0.27% |
| Price to Book | 6.34 x | - | 3.99 x | 1.38 x | 1.47 x | 0.99 x | 1.04 x | - |
| Nbr of stocks (in thousands) | 36,565 | 42,498 | 52,055 | 54,751 | 57,550 | 58,563 | - | - |
| Reference price 2 | 34.70 | 43.53 | 39.62 | 10.63 | 9.260 | 6.030 | 6.030 | 6.030 |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 2/28/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 154.9 | 188.8 | 241.9 | 276.2 | 295.9 | 308.6 | 344.6 | 391.2 |
| EBITDA 1 | -27.36 | -21.29 | -11.25 | -2.487 | 11.02 | 24.67 | 37.38 | 53.5 |
| EBIT 1 | -54.86 | -96.12 | -143.6 | -140 | -126.9 | -62.14 | -53.77 | -21.4 |
| Operating Margin | -35.41% | -50.9% | -59.38% | -50.68% | -42.88% | -20.14% | -15.61% | -5.47% |
| Earnings before Tax (EBT) 1 | -59.95 | -116.2 | -160.1 | -141.7 | -117.8 | -62.04 | -53.86 | -50.8 |
| Net income 1 | -60.1 | -115 | -153.2 | -137.4 | -118.1 | -62.57 | -54.74 | -50.8 |
| Net margin | -38.79% | -60.91% | -63.33% | -49.74% | -39.92% | -20.28% | -15.88% | -12.99% |
| EPS 2 | -1.657 | -2.910 | -3.230 | -2.630 | -2.090 | -0.9914 | -0.8220 | -0.3000 |
| Free Cash Flow 1 | -34.58 | -35.36 | -33.57 | -37.44 | -34.32 | -5 | -7.659 | -0.9475 |
| FCF margin | -22.32% | -18.73% | -13.88% | -13.55% | -11.6% | -1.62% | -2.22% | -0.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 2/28/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 61.74 | 64.72 | 68.09 | 70.63 | 68.35 | 69.16 | 73.87 | 73.21 | 73.77 | 75.08 | 74.79 | 75.61 | 78.09 | 80.13 | 83.4 |
| EBITDA 1 | -5.794 | -6.278 | 0.671 | 1.999 | -4.554 | -0.603 | 4.164 | 3.513 | 1.992 | 1.352 | 2.915 | 6.381 | 7.306 | 8.03 | 7.236 |
| EBIT 1 | -42.25 | -44.76 | -24.35 | -33.19 | -45.72 | -36.74 | -34.91 | -34.62 | -24.58 | -32.78 | -18.8 | -15.48 | -14.39 | -13.77 | -12.41 |
| Operating Margin | -68.43% | -69.17% | -35.76% | -46.99% | -66.89% | -53.13% | -47.27% | -47.28% | -33.32% | -43.66% | -25.14% | -20.47% | -18.43% | -17.18% | -14.88% |
| Earnings before Tax (EBT) 1 | -46.67 | -49.14 | -26.01 | -34.37 | -45.58 | -35.72 | -33.12 | -32.53 | -21.97 | -30.17 | -18.66 | -15.6 | -14.19 | -13.63 | -11.56 |
| Net income 1 | -40.01 | -48.99 | -22.46 | -33.43 | -45.74 | -35.78 | -33.19 | -32.61 | -22.03 | -30.31 | -18.9 | -15.84 | -14.51 | -13.72 | -11.9 |
| Net margin | -64.81% | -75.7% | -32.98% | -47.33% | -66.91% | -51.74% | -44.93% | -44.55% | -29.86% | -40.37% | -25.27% | -20.94% | -18.58% | -17.13% | -14.27% |
| EPS 2 | -0.8200 | -0.9400 | -0.4200 | -0.6200 | -0.8400 | -0.6600 | -0.6000 | -0.5800 | -0.3900 | -0.5300 | -0.3011 | -0.2486 | -0.2264 | -0.2127 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/4/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/2/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 330 | 311 | - |
| Net Cash position 1 | 180 | 102 | 264 | 137 | 89.7 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 13.37 x | 8.307 x | - |
| Free Cash Flow 1 | -34.6 | -35.4 | -33.6 | -37.4 | -34.3 | -5 | -7.66 | -0.95 |
| ROE (net income / shareholders' equity) | -51% | - | -38.4% | -2.96% | 2.2% | 5.91% | 9.56% | 15.6% |
| ROA (Net income/ Total Assets) | -29.1% | - | -21.7% | -1.77% | 1.2% | 3.01% | 4.38% | - |
| Assets 1 | 206.7 | - | 704.9 | 7,760 | -9,879 | -2,080 | -1,251 | - |
| Book Value Per Share 2 | 5.470 | - | 9.920 | 7.690 | 6.290 | 6.110 | 5.800 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.4 | 9.22 | 10.5 | 2.17 | - | 13.5 | 17.2 | 23.1 |
| Capex / Sales | 1.55% | 4.88% | 4.32% | 0.78% | - | 4.37% | 4.98% | 5.91% |
| Announcement Date | 2/27/20 | 2/25/21 | 3/1/22 | 2/28/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
6.03
USD
Average target price
12
USD
Spread / Average Target
+99.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.88% | 353M | |
| -19.95% | 214B | |
| -9.06% | 66.27B | |
| -3.37% | 56.38B | |
| -10.49% | 46.62B | |
| +8.30% | 43.93B | |
| -6.51% | 34.19B | |
| -7.95% | 29.14B | |
| +85.24% | 24.32B | |
| +3.45% | 21.64B |
- Stock Market
- Equities
- HCAT Stock
- Financials Health Catalyst, Inc.
